Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

20072,267 citationsJournal Article

Authors

Bruce J. Giantonio · Dana-Farber Cancer Institute

Paul J. Catalano · Thomas Jefferson University

Neal J. Meropol · University of Pennsylvania

Peter J. O’Dwyer · Thomas Jefferson University

Edith P. Mitchell · Mount Sinai Medical Center

Steven R. Alberts · Thomas Jefferson University

Michael Schwartz

Abstract

The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 12, pp. 1539-1544

DOI: 10.1200/jco.2006.09.6305

Field-Weighted Citation Impact: 85.02